High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

Blood

Volumn 113, Issue 5, 2009, Pages 995-1001

  Gyan, Emmanuel ^a   Foussard, Charles ^b   Bertrand, Philippe ^c   Michenet, Patrick ^d   Gouill, Steven Le ^e   Berthou, Christian ^f   Maisonneuve, Hervé ^d   Delwail, Vincent ^g   Gressin, Rémi ^h   Quittet, Philippe ⁱ   Vilque, Jean Pierre ^j   Desablens, Bernard ^k   Jaubert, Jérôme ^l   Ramée, Jean François ^m   Arakelyan, Nina ⁿ   Thyss, Antoine ^o   Cécile, Moluçon Chabrot ^p   Delépine, Roselyne ^a   Milpied, Noël ^q   Colombat, Philippe ^a   Deconinck, Eric ^r   more..

^a CHU BRETONNEAU   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d CENTRE HOSPITALIER   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g University of Poitiers   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j Anticancer Center François Baclesse   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^m Department of Hematology   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o Biol Devmt et Cancer CNRS UMR 6543   (United States)

^p UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^q BORDEAUX UNIVERSITY HOSPITAL   (France)

^r UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINDESINE; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; WHOLE BODY RADIATION; ADOLESCENT; AUTOTRANSPLANTATION; BONE MARROW PURGING; DISEASE FREE SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MORTALITY; SECOND CANCER; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; BONE MARROW PURGING; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASMS, SECOND PRIMARY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 60849131731     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-160200     Document Type: Article

References (43)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes; Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. Gibson J, Ho PJ, Joshua D. Low-grade lymphoma: the optimal timing. Transplant Proc. 2004;36:1995-1998.
3. Tse WW, Lazarus HM, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant. 2004;34:929-938.
4. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
7. Herold M, Dolken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol. 2003;82:77-79.
8. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-1992.
9. Salles GA, Foussard C, Nicolas M, et al. Rituximab added αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2004;104:Abstract 160.
10. Colombat P, Donadio D, Fouillard L, et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant. 1994;13:157-162.
11. Brice P, Simon D, Bouabdallah R, et al. Highdose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000;11:1585-1590.
12. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12: 1177-1184.
13. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325: 1525-1533.
14. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927.
15. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;108:2540-2544.
16. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:2667-2674.
17. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in highrisk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111: 4004-4013.
18. Deconinck E, Foussard C, Milpied N, et al. Highdose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105:3817-3823.
19. Robb-Smith AH. U.S. National Cancer Institute working formulation of non-Hodgkin's lymphomas for clinical use. Lancet. 1982;2:432-434.
20. Harris NL. Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Ann Oncol. 1997;8(Suppl 2):11-16.
21. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993; 329:1608-1614.
22. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
23. World Health Organization. World Health Organization Handbook for Reporting Results for Cancer Treatment. Geneva, Switzerland; 1979:38.
24. Colombat P, Cornillet P, Deconinck E, et al. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant. 2000;26:971-977.
25. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood. 2002;100:1141-1152.
27. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
28. Barosi G, Carella A, Lazzarino M, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica. 2005;90:1236-1257.
29. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332-2338.
30. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21:5-15.
31. Horning SJ, Chao NJ, Negrin RS, et al. Highdose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801-813.
32. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460-1468.
33. Montoto S, Canals C, Rohatiner AZ, et al. Longterm follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324-2331.
34. Howe R, Micallef IN, Inwards DJ, et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant. 2003;32: 317-324.
35. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554-2559.
36. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med. 2004;4:78-85.
37. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134: 596-601.
38. Freedman AS, Neuberg D, Mauch P, et al. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
39. Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by rituximab. Bone Marrow Transplant. 2003;32:57-63.
40. Belhadj K, Delfau-Larue MH, Elgnaoui T, et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol. 2004;15:504-510.
41. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, highdose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol. 2002;116:229-235.
42. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
43. Foussard C, Colombat P, Maisonneuve H, et al. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol. 2005;16:466-472.